Clinical trials: Controlled Diabetes
Diabetes, Diabetes Mellitus, Type 2
Impact of Dietary Intervention on Weight Change in Subjects With Type 2 Diabetes
This trial is conducted in Europe, and North and South America. The aim of this trial is to investigate if a dietary intervention has an effect on weight when initiating insulin treatment in subjects with type 2 diabetes…
- Trial name
- DIET™ (NCT01232491)
- Testing
- Insulin detemir, Dietary regimen
- Where
- 112 sites in United States, Argentina and 9 more
- Volunteers
- 611 people
- Sponsor
- Novo Nordisk A/S
Type 1 Diabetes
Extended Bolus for Meals in a Closed-loop System
This study aims to evaluate whether the use of an extended bolus will improve glucose control with high-fat high protein meals using a closed-loop system.
- Trial name
- NCT05454891
- Testing
- Tandem t:slim X2 insulin pump: Extended bolus of insulin then standard bolus of insulin, Tandem t:slim X2 insulin pump: Standard bolus of insulin then extended bolus of insulin
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- University of California, San Francisco
Diabetes Mellitus, Type 2
Efficacy and Safety of B I1356 (Linagliptin) vs. Placebo Added to Metformin Background Therapy in Patients With Type 2 Diabetes
The objective of the current study is to investigate the efficacy, safety and tolerability of BI 1356 (5 mg once daily) compared to placebo given for 24 weeks as add-on therapy to metformin in patients with type 2 diabetes…
- Trial name
- NCT00601250
- Testing
- linagliptin
- Where
- 82 sites in United States, Czechia and 8 more
- Volunteers
- 701 people
- Sponsor
- Boehringer Ingelheim
Diabetes Mellitus, Type 2
Dose Finding, Safety and Efficacy of Monthly Subcutaneous Canakinumab Administration in Metformin Monotherapy Treated Type 2 Diabetic Patients
This was a four month dose ranging study followed by a 24 to 48 month extension at the selected dose to characterize the safety and efficacy of the injectable IL-1B (interleukin 1, beta) antagonist canakinumab in the treatment of…
- Trial name
- NCT00900146
- Testing
- Canakinumab, Metformin
- Where
- 106 sites in United States, Argentina and 12 more
- Volunteers
- 556 people
- Sponsor
- Novartis
Diabetes Mellitus, Type 2
A Research Study to See How Well the New Weekly Medicine IcoSema, Which is a Combination of Insulin Icodec and Semaglutide, Controls Blood Sugar Level in People With Type 2 Diabetes Compared to Weekly Insulin Icodec
This study will compare the new medicine IcoSema, which is a combination of insulin icodec and semaglutide, taken once a week, to insulin icodec taken once a week in people with type 2 diabetes.
- Trial name
- COMBINE 1 (NCT05352815)
- Testing
- IcoSema, Insulin icodec
- Where
- 281 sites in United States, Australia and 20 more
- Volunteers
- 1,291 people
- Sponsor
- Novo Nordisk A/S
Diabetes, Diabetes Mellitus, Type 2
Comparison of NN1250 With Insulin Glargine in Type 2 Diabetes
This trial is conducted in Africa, Asia, Europe and South America. The aim of this clinical trial is to compare NN1250 (insulin degludec (IDeg) with insulin glargine (IGlar) in patients with type 2 diabetes.
- Trial name
- BEGIN™ (NCT01006291)
- Testing
- insulin degludec, insulin glargine
- Where
- 72 sites in Argentina, Finland and 12 more
- Volunteers
- 687 people
- Sponsor
- Novo Nordisk A/S
Type 1 Diabetes Mellitus
Pivotal Omnipod Horizon™ Automated Glucose Control System
Subjects will undergo a 14-day outpatient, standard therapy phase during which sensor and insulin data will be collected. This will be followed by a 94-day (13-week) hybrid closed-loop phase conducted in an outpatient setting and…
- Trial name
- NCT04196140
- Testing
- Omnipod Horizon™ Automated Glucose Control System
- Where
- 16 sites in United States
- Volunteers
- 240 people
- Sponsor
- Insulet Corporation
Type II Diabetes Mellitus, Renal Insufficiency
A Study to Look at the Effect MEDI0382 Has on Blood Sugar in People With Type 2 Diabetes and Kidney Problems and Also to Check That MEDI0382 is Well Tolerated
A study to look at the effect MEDI0382 has on blood sugar in people with type 2 diabetes and kidney problems and also to check that MEDI0382 is well tolerated.
- Trial name
- NCT03550378
- Testing
- MEDI0382
- Where
- 7 sites in Germany, United Kingdom
- Volunteers
- 41 people
- Sponsor
- MedImmune LLC
Type 2 Diabetes Mellitus
Phase IV Study With a 36-week Extension Period to Evaluate the Efficacy and Safety of Dapagliflozin Therapy When Added to the Therapy of Japanese Patients With Type 2 Diabetes With Inadequate Glycemic Control on Insulin.
Japanese male and female patients with Type 2 Diabetes and aged ≥ 20 years old, with inadequate glycemic control on insulin defined as Haemoglobin A1c ≥ 7.2% and < 11% will be enrolled into the wash-out phase or directly into the…
- Trial name
- NCT02157298
- Testing
- Dapagliflozin 5 mg
- Where
- 14 sites in Japan
- Volunteers
- 266 people
- Sponsor
- AstraZeneca
Obesity, Impaired Glucose Tolerance
The Effect of Exenatide on Weight and Hunger in Obese, Healthy Women
This study will look at the effect of exenatide, a drug which has been approved for the treatment of type 2 diabetes, on body weight, appetite and energy expenditure among moderately obese women without diabetes.
- Trial name
- NCT00456885
- Testing
- exenatide
- Where
- United States
- Volunteers
- 41 people, healthy volunteers welcome
- Sponsor
- Beth Israel Deaconess Medical Center
Gastroparesis
Temporary Gastric Electrical Stimulation for Drug Refractory Gastroparesis
The purpose of this research is to determine if temporary gastric electrical stimulation will help improve symptoms of gastroparesis (abnormal stomach emptying).
- Trial name
- NCT00432835
- Testing
- Gastric Electrical Stimulator, Enterra, Medtronics, Inc.
- Where
- United States
- Volunteers
- 58 people
- Sponsor
- University of Mississippi Medical Center
Type 2 Diabetes, Diabetes Mellitus, Type 2
A Study of Tirzepatide (LY3298176) in Adults With Type 2 Diabetes Switching From a GLP-1 RA (SURPASS-SWITCH-2)
The main purpose of this study is to investigate the effects of switching from glucagon-like peptide-1 receptor agonist (GLP-1 RA) therapy to tirzepatide glucose-dependent insulinotropic polypeptide (GIP) GLP-1 RA agonist in…
- Trial name
- NCT05706506
- Testing
- Tirzepatide
- Where
- 32 sites in United States
- Volunteers
- 152 people
- Sponsor
- Eli Lilly and Company
Diabetes, Diabetes Mellitus, Type 2
Liraglutide Effect and Action in Diabetes: Evaluation of Cardiovascular Outcome Results
This trial is conducted in Africa, Asia, Europe, and North and South America. The aim of this trial is to determine the long term effect of liraglutide on cardiovascular events in subjects with type 2 diabetes.
- Trial name
- LEADER® (NCT01179048)
- Testing
- liraglutide
- Where
- 428 sites in United States, Australia and 31 more
- Volunteers
- 9,341 people
- Sponsor
- Novo Nordisk A/S
Type 2 Diabetes Mellitus
A Psychological-behavioral Intervention to Increase Activity in Type 2 Diabetes
The focus of this study is to examine the feasibility, acceptability, and impact of a customized, combined positive psychology and motivational interviewing (PP-MI) health behavior intervention in a group of patients with type 2…
- Trial name
- BEHOLD-16 (NCT03164538)
- Testing
- Positive Psychology + Motivational Interviewing, Diabetes Education
- Where
- United States
- Volunteers
- 70 people
- Sponsor
- Massachusetts General Hospital
Diabetes Mellitus Type 2
GLP-1 Receptor Agonist Lixisenatide in Patients With Type 2 Diabetes for Glycemic Control and Safety Evaluation, on Top of Pioglitazone
The purpose of this study is to evaluate the benefits and risks of lixisenatide (AVE0010), in comparison to placebo, as an add-on treatment to pioglitazone with or without metformin, over a period of 24 weeks of treatment…
- Trial name
- GETGOAL-P (NCT00763815)
- Testing
- Lixisenatide (AVE0010), Pen auto-injector, Pioglitazone
- Where
- 150 sites in United States, Austria and 11 more
- Volunteers
- 484 people
- Sponsor
- Sanofi
Diabetes
Ileal Interposition With Sleeve Gastrectomy for Control of Diabetes
Ileal interposition shifts a segment of ileum proximally to achieve maximal meal stimulated Glucagon-Like Peptide-1 secretion and coupled with a limited/complete sleeve gastrectomy (depending on the Body Mass Index), for Ghrelin…
- Trial name
- IISG (NCT00834626)
- Testing
- Ileal Interposition with Sleeve Gastrectomy
- Where
- India
- Volunteers
- 30 people
- Sponsor
- Kirloskar Hospital
Type2 Diabetes, High Blood Sugar
Evaluate Safety as Mono or Combination Therapies With Anti-diabetes Mellitus Drugs in Japanese Subjects With Type 2 Diabetes Mellitus
This is a long term, single arm, open label study to evaluate the safety and efficacy of dapagliflozin as monotherapy or in combination therapy with other anti diabetic drug in Japanese subjects with type 2 diabetes mellitus who…
- Trial name
- NCT01294436
- Testing
- Dapagliflozin
- Where
- 38 sites in Japan
- Volunteers
- 728 people
- Sponsor
- AstraZeneca
Diabetes Mellitus, Type 2
Efficacy and Safety of Linagliptin in Combination With Insulin in Patients With Type 2 Diabetes
The objective of the current study is to investigate the efficacy, safety and tolerability of linagliptin (5 mg / once daily) compared to Placebo during long term treatment (52 weeks and longer) in combination with basal insulin…
- Trial name
- NCT00954447
- Testing
- Linagliptin
- Where
- 169 sites in United States, Argentina and 17 more
- Volunteers
- 1,263 people
- Sponsor
- Boehringer Ingelheim
Type 2 Diabetes Mellitus
Efficacy and Safety of Sotagliflozin Versus Glimepiride and Placebo in Participants With Type 2 Diabetes Mellitus That Are Taking Metformin Monotherapy
Primary Objective: To demonstrate the non-inferiority of Sotagliflozin 400 milligrams (mg) compared to Glimepiride on hemoglobin A1c (HbA1c) reduction at Week 52 in participants with Type 2 Diabetes (T2D) who have inadequate…
- Trial name
- SOTA-GLIM (NCT03332771)
- Testing
- Sotagliflozin (SAR439954), Glimepiride, Metformin
- Where
- 142 sites in United States, Bulgaria and 2 more
- Volunteers
- 954 people
- Sponsor
- Lexicon Pharmaceuticals
Painful Diabetic Neuropathy
Efficacy and Safety of MEDI7352 in Participants With Painful Diabetic Neuropathy
This is a study investigating the effect of MEDI7352 on chronic pain in participants with painful diabetic neuropathy. The study incudes a screening period of up to 45 days and a 12-week treatment period during which MEDI7352 or…
- Trial name
- NCT03755934
- Testing
- MEDI7352
- Where
- 31 sites in Denmark, Hungary and 3 more
- Volunteers
- 112 people
- Sponsor
- AstraZeneca
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.